Table 4.

Evaluation of adalimumab expressed by the benefit estimated in percentage

Author	Dose (mg/sem)	Time of follow-up	PASI 50 (%)	PASI 75 (%)	PASI 90 (%)	PASI 100 (%)	PGA (%)
Cai L (145)	40 + 80	12 weeks		77.8			80.5
Reich K (136)	80 + 40	16 weeks		79.6		16.7
Revicki D (170)	80 + 40	16 weeks		64	43	19
Asahina A (143)	40 every 2 weeks	16 weeks		57.9
Asashina A (143)	0 every 2 weeks + 40 from week 2	16 weeks		62.8
Asashina A (143)	80 every 2 weeks	16 weeks		81
Gordon KB (150)	80 + 40 from week 1	12 weeks		49
Gordon KB (150)	80 + 40 from week 2	12 weeks		76
Saurat JH (137)	80 + 40 from week 2	16 weeks		79.6